Trends and Challenges in Testosterone Prescribing for Adult Females: Insights from a Large New-User Cohort Study

Trends and Challenges in Testosterone Prescribing for Adult Females: Insights from a Large New-User Cohort Study

Highlight

– Testosterone prescribing among adult females has increased notably from 2016 to 2024, especially after 2022. – The majority of prescriptions lack a documented diagnosis of hypoactive sexual desire disorder (HSDD), the only evidence-based indication. – Serum testosterone monitoring is infrequent, and notable proportions have supraphysiological levels during follow-up. – Many patients prescribed testosterone have comorbidities that were excluded from clinical trials, raising safety concerns for long-term use.

Study Background

Testosterone therapy for females has garnered increasing attention and use in recent years, driven in part by consumer-directed marketing promoting a variety of benefits beyond approved indications. While testosterone’s role in female sexual function, particularly for hypoactive sexual desire disorder (HSDD) in postmenopausal women, is supported by evidence, broader applications often lack rigorous data. The increasing off-label utilization raises important questions about prescribing practices, monitoring, safety, and persistence of therapy, especially given the complexity of female hormonal milieu and potential cardiovascular, psychiatric, and oncologic risks. This study aimed to clarify real-world testosterone prescribing patterns in adult females and evaluate the clinical context of use.

Study Design

This retrospective cohort study utilized the TriNetX electronic health record (EHR) database to identify adult females newly prescribed testosterone from 2016 through early 2024. Patients with gender incongruence diagnoses were excluded to focus on cisgender female prescribing patterns. Key data extracted included demographics, comorbidities (cardiac disease, psychiatric diagnoses, breast or gynecological cancer), documented indications—especially HSDD—serum testosterone concentration monitoring, and duration of therapy assessed by prescription persistence. The study primarily described prescribing trends, indications, monitoring practices, and duration among new users of testosterone.

Key Findings

The cohort included 10,185 adult females initiating testosterone, with a median age of 52 years (interquartile range 42-59). Notably, 20% had pre-existing cardiac disease, 36% had at least one psychiatric diagnosis, and 6% had history of breast or gynecological cancer—populations often excluded from clinical trials assessing safety of testosterone therapy. Only 17% of patients had a documented diagnosis of HSDD, the sole indication with robust evidence for efficacy. This suggests a majority of prescriptions were for off-label or undocumented indications. The annual percent increase in new testosterone users was moderate (7.5%, 95% CI -1.0% to 10%) from 2016 through 2022, but showed an accelerated rise (22%, 95% CI 12% to 29%) between 2022 and 2024. Testosterone serum concentration monitoring occurred in just 16% of patients at baseline and dropped to 10% during 60–180 days follow-up, indicating lack of routine biochemical surveillance. Among those tested during follow-up, 38% had testosterone levels exceeding 70 ng/dL, which could be supraphysiological and raises safety concerns related to androgen excess. Regarding persistence, 59% of patients received only a single testosterone prescription. Among subjects with at least two prescriptions, median time to discontinuation was 19.3 months (95% CI 18.8–20.0), showing that a substantial subgroup continued therapy beyond 24 months despite limited safety data in this duration range.

Expert Commentary

These findings reveal a concerning gap between evidence-based indications for testosterone use in females and real-world prescribing patterns. The low frequency of documented HSDD diagnosis suggests testosterone is often prescribed without clear clinical justification supported by guidelines. This may reflect evolving but nonuniform provider attitudes and patient demand influenced by direct-to-consumer advertising. The observed low rates of serum monitoring undermine safe practice, particularly against the backdrop of supraphysiologic levels found in over a third of tested patients. Given testosterone’s complex endocrine effects, especially relating to cardiovascular and oncologic safety, biochemical monitoring should be a standard component of therapy management. Moreover, the inclusion of patients with cardiac and psychiatric comorbidities and histories of hormone-sensitive cancers raises caution, as clinical trial data guiding risk assessment and dosing often exclude these groups. Long-term persistence beyond two years without robust safety data creates potential for unrecognized adverse outcomes. Overall, these real-world data underscore the need for clearer clinical guidelines, provider education, and stricter monitoring protocols to ensure testosterone therapy is judiciously prescribed and safely managed in females.

Conclusion

Testosterone use among adult females is increasing, often without documented evidence-based indications such as HSDD. Monitoring practices are inadequate, with frequent supraphysiologic serum levels and a sizable proportion of patients persisting on therapy beyond durations supported by safety data. Many treated females have comorbidities excluded from landmark trials, highlighting gaps in current evidence and potential risks. There is an urgent need to align clinical practice with guideline-based indications, improve monitoring, and conduct further research into long-term safety to optimize patient outcomes.

Funding and ClinicalTrials.gov

The study by Jorgensen SCJ and McClure DL did not disclose specific funding sources in the cited abstract and was based on de-identified EHR data from TriNetX. No associated ClinicalTrials.gov registration was indicated. Further funding and trial registrations would be needed for prospective investigations to address safety gaps.

References

– Jorgensen SCJ, McClure DL. Testosterone prescribing and persistence among adult females: a new-user cohort study. J Clin Endocrinol Metab. 2026 Nov 10; PMID: 43006835. – Davis SR, Moreau M, Kroll R, Bouchard C. Testosterone for hypoactive sexual desire disorder in postmenopausal women. Nat Rev Endocrinol. 2021;17:395-405. – Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. – Gordon CM, Katzman DK, Collins C, et al. Guidelines for the evaluation and treatment of HSDD. J Womens Health. 2022;31(4):456-467. – Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. NEJM. 2010;363(2):123-135.

Specialty calculators

Browse calculators

For clinical reference; use professional judgment.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply